Clinical AML Registry and Biomaterial Database of the AML Cooparative Group (AML-CG)
Recruiting
- Conditions
- C92.0C92.4C92.5C92.6C92.7C92.8C92.9C93.0C94.0C94.2
- Registration Number
- DRKS00020816
- Lead Sponsor
- Klinikum der Universität München, Campus Großhadern
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 3500
Inclusion Criteria
AML as defined by WHO criteria (including acute promyelocytic leukemia (APL) ); Age >= 18 years; signed informed consent
Exclusion Criteria
None
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Descriptive statistical analysis on baseline parameters at initial diagnosis (blood laboratory, morphology, cytogenetics, immuno phenotype molecular biology).<br>Description of therapy regimens (induktion therapy, consolidation, stem cell transplantation, maintenance therapy, palliative cytoreduction, hypomethylating substances). Description of the course of the disease (therapy success, relapse, survival, toxcicities)
- Secondary Outcome Measures
Name Time Method Recruitment success; explorative new research questions
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie acute myeloid leukaemia subtypes in DRKS00020816 AML-CG registry?
How does DRKS00020816 AML-CG registry compare to other observational studies in AML treatment outcomes?
What biomarkers are being evaluated in DRKS00020816 for predicting response to AML therapies?
What adverse events are associated with current AML treatments and how might DRKS00020816 inform management strategies?
What combination therapies are being explored in DRKS00020816 for AML subtypes like PML and 11q23-abnormality?